354 related articles for article (PubMed ID: 25785551)
21. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
[TBL] [Abstract][Full Text] [Related]
23. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P; Romanus D; Palumbo A; Luptakova K; Rifkin RM; Tran LM; Raju A; Farrelly E; Noga SJ; Blazer M; Chari A
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):152-160. PubMed ID: 29395837
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
25. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Song X; Cong Z; Wilson K
Curr Med Res Opin; 2016; 32(1):95-103. PubMed ID: 26488820
[TBL] [Abstract][Full Text] [Related]
26. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant.
Ailawadhi S; Ogbonnaya A; Murty S; Cherepanov D; Schroader BK; Romanus D; Farrelly E; Chari A
Cancer Med; 2023 Feb; 12(3):3145-3159. PubMed ID: 36151787
[TBL] [Abstract][Full Text] [Related]
27. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
LeBlanc R; Hollmann S; Tay J
J Popul Ther Clin Pharmacol; 2016; 23(1):e103-13. PubMed ID: 27337740
[TBL] [Abstract][Full Text] [Related]
28. Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma.
Castelli R; Pantaleo G; Gallipoli P; Gidaro A; Arquati M; Wu MA; Lambertenghi Deliliers G
Anticancer Drugs; 2015 Nov; 26(10):1078-82. PubMed ID: 26295869
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Brown RE; Stern S; Dhanasiri S; Schey S
Eur J Health Econ; 2013 Jun; 14(3):507-14. PubMed ID: 22572968
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
32. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
[TBL] [Abstract][Full Text] [Related]
33. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
Zamagni E; Dhanasiri S; Ghale A; Moore A; Roussel M
Leuk Lymphoma; 2021 Oct; 62(10):2492-2501. PubMed ID: 34121589
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
[TBL] [Abstract][Full Text] [Related]
35. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
36. Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
Cheng CN; Huang SY; Lien PW; Huang ST; Lin FJ
PLoS One; 2021; 16(5):e0252124. PubMed ID: 34038463
[TBL] [Abstract][Full Text] [Related]
37. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Lu J; Chen W
J Comp Eff Res; 2019 Sep; 8(12):979-992. PubMed ID: 31232089
[No Abstract] [Full Text] [Related]
39. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
40. A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients.
Elsisi GH; Carapinha JL; Afify R; Elmoty MA; Khalaf M
J Med Econ; 2020 Oct; 23(10):1168-1175. PubMed ID: 32669063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]